Cite

HARVARD Citation

    Liu, R. et al. (2021). Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors. Therapeutic advances in medical oncology. p. . [Online]. 
  
Back to record